{
    "nctId": "NCT05765357",
    "briefTitle": "Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin\u00ae in Healthy Male Volunteers",
    "officialTitle": "Phase I Clinical Study of Randomized, Double-blind, Single-dose, Parallel Comparison of Trastuzumab for Injection and Herceptin\u00ae in Healthy Male Volunteers on Pharmacokinetics and Safety",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer, Metastatic Gastric Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 89,
    "primaryOutcomeMeasure": "Area under drug concentration - time curve (AUC0-t)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Fully understand the purpose of the trial, and have a basic understanding of the pharmacological effects and possible adverse reactions of the drug under study; Voluntary written informed consent in accordance with the Helsinki Declaration;\n* Healthy male subjects aged \u2265 18 years and \u2264 65 years;\n* Body weight \u2265 50 kg \u2264 90 kg, body mass index \u2265 18 \u2264 28kg/m2;\n* The system examination indicators were within the normal range, or the examination results were abnormal but the researchers judged that there was no clinical significance;\n* Subjects agree to use reliable contraceptive methods for both themselves and their partners during the study period and for 6 months after the study drug infusion.\n\nExclusion Criteria:\n\n* History of hypertension or abnormal blood pressure at screening/baseline measurement;\n* A history of albuminuria or albuminuria as assessed by the investigator as clinically significant;\n* Received any antibody or protein targeting Vascular Endothelial Cell Growth Factor (VEGF) or VEGF receptors in the previous 1 year;\n* Study the use of any biological product or live virus vaccine within 3 months prior to drug infusion, or the use of any monoclonal antibody within 12 months;\n* Have an inherited tendency to bleed or have coagulation dysfunction, or have a history of thrombosis or bleeding;\n* History of digestive tract perforation or digestive tract fistula;\n* Unhealed wound ulcers or fractures, or major surgery within 2 months prior to randomization or expected to be performed during the study period or within 2 months after study completion;\n* Use of a prescription or over-the-counter drug or nutritional supplement within the 5 half-life of the drug or nutritional supplement or within 2 weeks prior to the study drug use;\n* Positive virology test;\n* Known allergy to trastuzumab;\n* Known history of allergic diseases or allergic constitution;\n* Study the history of blood donation 3 months before drug infusion;\n* Received any other investigational drug therapy or participated in another interventional clinical trial within 2 months prior to screening\n* A history of alcohol or drug abuse in the 12 months prior to screening;\n* A history of mental illness;\n* Subjects whose spouses plan to become pregnant;\n* The study cannot be completed according to protocol requirements during the study period;\n* Conditions considered unsuitable for inclusion by other researchers.",
    "sex": "MALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}